1 option
Investing in Ex Ante Regulation: Evidence from Pharmaceutical Patent Examination / Michael D. Frakes, Melissa F. Wasserman.
- Format:
- Book
- Author/Creator:
- Frakes, Michael D.
- Series:
- Working Paper Series (National Bureau of Economic Research) no. w27579.
- NBER working paper series no. w27579
- Language:
- English
- Physical Description:
- 1 online resource: illustrations (black and white);
- Place of Publication:
- Cambridge, Mass. National Bureau of Economic Research 2020.
- Summary:
- We explore how the Patent Office may improve the quality of issued patents on "secondary" drug features by giving examiners more time to review drug-patent applications. Our findings suggest that current time allocations are causing examiners to issue low quality secondary patents on the margin. To assess the merits of expanding ex ante scrutiny of drug-patent applications at the agency, we set forth estimates of the various gains and losses associated with giving examiners more time, including reduced downstream litigation costs and added personnel expenses, along with both the static gains and dynamic innovation losses associated with earlier generic entry.
- Notes:
- Print version record
- July 2020.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.